Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC

Gao, SG; Li, N; Gao, SY; Xue, Q; Ying, JM; Wang, SH; Tao, XL; Zhao, J; Mao, YS; Wang, B; Shao, K; Lei, WD; Wang, DL; Lv, F; Zhao, L; Zhang, F; Zhao, ZR; Su, K; Tan, FW; Gao, YB; Sun, N; Wu, DW; Yu, Y; Ling, Y; Wang, ZJ; Duan, CJ; Tang, W; Zhang, L; He, S; Wu, N; Wang, J; He, J

He, J (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Thorac Surg Dept,Canc Hosp, Panjiayuan Nanli 17, Beijing 100021, Peoples R China.

JOURNAL OF THORACIC ONCOLOGY, 2020; 15 (5): 816

Abstract

Introduction: Programmed death receptor-1 (PD-1) inhibitors have shown efficacy in first-line treatment of NSCLC; however, evidence of PD-1 inhibitor ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索